Vera Therapeutics, Inc. (NASDAQ:VERA) highlighted as one of the best small-cap biotech stocks to buy by analysts. H.C. Wainwright raised price target to $90 with a “Buy” rating, anticipating strong revenue growth from atacicept in IgA nephropathy. Phase 3 trial results for late-stage kidney disease treatment showed promising outcomes, reducing proteinuria by 46% and ensuring safety. Investor confidence and regulatory progress strengthened as Vera moves towards filing for U.S. review with positive clinical validation in nephrology. Focus on developing therapies for severe immunological and renal diseases.

Read more at Yahoo Finance: H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth